Researchers identified 23,450 trial sites; a majority of them began before 2020. The main features of intestinal inflammation are reproduced as a biomarker for response to immune checkpoint inhibition. There was a 29% increase in cancer detection with AI-supported screening. Researchers found two effective treatments for metaplastic breast cancer. Subgroup analyses of multiple diagnostic performance metrics in high vs low-income communities were also performed. New research has uncovered a combination therapy that shows promising results in melanoma and breast cancer models. A study compared the screening performances of a tools used in cervical cancer screening in HIV-positive women. Aliya Omer, AstraZeneca, talks about data that backs the efficacy of olaparib in treating high-risk early breast cancer. Results were deduced from self-collected as well as clinician-obtained screening results. In patients with high-risk HER2-psoitive breast cancer, adjuvant trastuzumab emtansine reduces the long-term risk of death. A recent study shows that macrophages can be used to predict whether or not a melanoma patient will respond to chemotherapy. The study used SEER data of nearly 20,000 cases. A groundbreaking study has demonstrated that artificial intelligence can enhance breast cancer detection rates by almost 20%. New research on active monitoring versus surgery in DCIS was presented at SABCS 2024. A team of researchers aimed to analyze the genetic expression and prognostic value of selenoprotein gene mutations. A recent study found a connection between total serum calcium levels and developing melanoma. People diagnosed with metastatic breast cancer have a notably increased risk of developing heart disease. Dr. Sadie Debrozsi discusses the importance of "pan-cancer" testing, especially as it pertains to breast cancer. Dr. John Fruehauf provided an in-depth overview of treatments for metastatic melanoma. The primary outcomes of the study were melanoma-related deaths and nonmelanoma-related deaths.